Evotec AG, of Hamburg, Germany, said it advanced a drug into phase I development under its multitarget endometriosis alliance with Leverkusen, Germany-based Bayer AG, triggering an undisclosed milestone payment to Evotec, which is also eligible for other clinical and sales milestones as well as royalties on net sales.